242 related articles for article (PubMed ID: 20003286)
21. Durable remission in a patient with
Neil AJ; Muto MG; Kolin DL; Konstantinopoulos PA
Gynecol Oncol Rep; 2023 Aug; 48():101237. PubMed ID: 37449085
[TBL] [Abstract][Full Text] [Related]
22. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer.
Ménard S; Casalini P; Campiglio M; Pupa S; Agresti R; Tagliabue E
Ann Oncol; 2001; 12 Suppl 1():S15-9. PubMed ID: 11521715
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.
Santin AD; Bellone S; Roman JJ; McKenney JK; Pecorelli S
Int J Gynaecol Obstet; 2008 Aug; 102(2):128-31. PubMed ID: 18555254
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
Nishimura R; Okumura Y; Arima N
Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
[TBL] [Abstract][Full Text] [Related]
25. HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer.
Chay WY; Chew SH; Ong WS; Busmanis I; Li X; Thung S; Ngo L; Lim SL; Lim YK; Chia YN; Koh E; Pang C; Soh LT; Wang J; Ho TH; Tay SK; Lim-Tan SK; Lim KH; Chia JW; Goh LK
PLoS One; 2013; 8(4):e61565. PubMed ID: 23620766
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ; Press M
J Clin Oncol; 2002 Feb; 20(3):719-26. PubMed ID: 11821453
[TBL] [Abstract][Full Text] [Related]
27. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
[TBL] [Abstract][Full Text] [Related]
28. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
Diaz NM
Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
[TBL] [Abstract][Full Text] [Related]
29. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
Dowsett M; Procter M; McCaskill-Stevens W; de Azambuja E; Dafni U; Rueschoff J; Jordan B; Dolci S; Abramovitz M; Stoss O; Viale G; Gelber RD; Piccart-Gebhart M; Leyland-Jones B
J Clin Oncol; 2009 Jun; 27(18):2962-9. PubMed ID: 19364966
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic features of unexpectedly HER2 positive breast carcinomas: An institutional experience.
LaBoy C; Siziopikou KP; Rosen L; Blanco LZ; Pincus JL
Pathol Res Pract; 2021 Jun; 222():153441. PubMed ID: 33857853
[TBL] [Abstract][Full Text] [Related]
31. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
32. Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.
Han HS; Kim JS; Park JH; Jeon YK; Lee KW; Oh DY; Kim JH; Park SY; Im SA; Kim TY; Park IA; Bang YJ
J Korean Med Sci; 2009 Oct; 24(5):910-7. PubMed ID: 19794992
[TBL] [Abstract][Full Text] [Related]
33. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
[TBL] [Abstract][Full Text] [Related]
34. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'.
Lee KR; Scully RE
Am J Surg Pathol; 2000 Nov; 24(11):1447-64. PubMed ID: 11075847
[TBL] [Abstract][Full Text] [Related]
35. [Molecular protocol for HER2/neu analysis in breast carcinoma].
Artufel MV; Valero AC; Lladó RR; Sagalés NE; Llorca MC; Carazo AM; Cardó CC; Torrus XP
Clin Transl Oncol; 2005 Dec; 7(11):504-11. PubMed ID: 16373062
[TBL] [Abstract][Full Text] [Related]
36. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.
Bamias A; Psaltopoulou T; Sotiropoulou M; Haidopoulos D; Lianos E; Bournakis E; Papadimitriou C; Rodolakis A; Vlahos G; Dimopoulos MA
Cancer; 2010 Mar; 116(6):1462-8. PubMed ID: 20108307
[TBL] [Abstract][Full Text] [Related]
37. Fertility-Sparing Surgery and Adjuvant Chemotherapy with Trastuzumab Result in Complete Remission in a Young Woman with Rare Primary Mucinous Ovarian Cancer due to ERBB2 Co-amplification with CDK12 and Chromosome 11q13.3 Amplicon: A Case Report and Literature Review.
Gao L; Huang T; Zhong L; Peng L; Huang Z; Lu Y
Reprod Sci; 2024 Jun; 31(6):1626-1631. PubMed ID: 38216775
[TBL] [Abstract][Full Text] [Related]
38. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
39. Targeting HER2 in other tumor types.
Scholl S; Beuzeboc P; Pouillart P
Ann Oncol; 2001; 12 Suppl 1():S81-7. PubMed ID: 11521727
[TBL] [Abstract][Full Text] [Related]
40. High frequency of BRAF mutations in primary mucinous ovarian carcinoma of Taiwanese patients.
Chao WR; Lee YJ; Lee MY; Sheu GT; Han CP
Taiwan J Obstet Gynecol; 2021 Nov; 60(6):1072-1077. PubMed ID: 34794740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
